All News

Panelists discussed 4 trials, which focused on 3 different ADCs and how each one is being utilized in their clinical practice.

Among 3-to-25-year-old patients with slow, early responses to chemotherapy with newly diagnosed classic Hodgkin lymphoma, pembrolizumab showed an ORR of 98%.

The phase 2 AMPLIFY-7P trial did not meet its primary DFS end point, though post-hoc analyses identified a benefit in R0-resected patients with mKRAS PDAC.

Data from a phase 2 trial support further clinical development of AK117 in previously untreated acute myeloid leukemia.

The FDA has accepted the BLA for ozekibart in unresectable or metastatic conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027.

Emmanuel Bachy, MD, PhD, shared data from a phase 1b study evaluating subcutaneous mosunetuzumab plus lenalidomide in untreated follicular lymphoma.

This prospective, single-arm observational trial examines whether aromatase inhibitor therapy in postmenopausal women with HR-positive breast cancer adversely affects cardiorespiratory fitness, skeletal muscle function, and immunosenescence.

This randomized multicenter pilot trial assesses feasibility of the THRIVE Wellness Program, a 6-week lifestyle intervention for young breast cancer survivors aged 40 years or younger.

Data from a phase 1/2 trial show durable disease control with belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.

The FDA has approved gadoquatrane for contrast-enhanced MRI to detect lesions with abnormal vascularity in the central nervous system and body.

Brentuximab vedotin plus ifosfamide, carboplatin, and etoposide conferred significantly increased toxicity vs 2 other chemotherapy-containing regimens.

Early interim data from the 3 patients with recurrent glioblastoma showed 100% local disease control and a 67% complete response rate with Alpha DaRT.

Phase 1 data support arlo-cel as a potentially effective early-line treatment option for those with relapsed/refractory multiple myeloma.

Daniel C. McFarland, DO, sat down with psycho-oncology expert Kaleena Chilcote, MD, to discuss the complexities of personality disorders in the cancer clinic.

Survey of safety-net breast cancer patients links stronger faith to greater trust in doctors, especially among Black and lower-income groups.

Explore how breast cancer stem cell plasticity, epigenetic reprogramming, and single-cell insights drive therapy resistance, revealing new targets to improve durable responses.

Updated phase 1/1b BGB-11417-101 trial data showed sonrotoclax 320 mg plus zanubrutinib achieved uMRD4 rates exceeding 90% in treatment-naive CLL/SLL.

Emmanuel Bachy, MD, PhD, highlighted high efficacy, durable responses, and a favorable adverse effect profile in follicular lymphoma with high tumor burden.

In BRUIN CLL-322, fixed-duration pirtobrutinib plus venetoclax/rituximab improved PFS vs venetoclax/rituximab in relapsed/refractory CLL.

Combining pirtobrutinib with venetoclax/rituximab yielded high MRD clearance among those with CLL/SLL in the phase 3 BRUIN CLL-322 trial.

In KOMET-007, ziftomenib plus 7+3 produced high responses and MRD-negativity rates in newly diagnosed NPM1-mutated or KMT2A-rearranged AML.

The safety profile of the CAR T-cell product in the real world was consistent with that observed in the TRANSCEND MCL study.

No new safety signals were observed with the LAG-3 inhibitor-based therapy among patients with relapsed/refractory classic Hodgkin lymphoma.

Explore how newer HER2 therapies and anthracycline-sparing regimens cut breast cancer heart damage, with monitoring and cardioprotective drugs.

Real-world study shows T-DXd benefits older metastatic breast cancer patients, but higher ILD risk and toxicity-driven discontinuation demand close monitoring, especially in octogenarians.

The brentuximab vedotin-based regimen was consistently favored in sensitivity analyses regardless of covariate adjustment tested.

The use of CD20×CD3 bispecific antibodies correlated with lower hematologic toxicity, higher responses, and preserved CAR T fitness in LBCL groups.

MRD responses appeared to be more favorable with the use of blinatumomab among pediatric patients with high-risk B-cell acute lymphoblastic leukemia.

The phase 3 EPCORE DLBCL-1 data showed epcoritamab reduced progression or death risk by 26% vs chemoimmunotherapy in relapsed/refractory LBCL.

In MonumenTAL-3, talquetamab plus daratumumab with or without pomalidomide significantly improved PFS vs DPd in relapsed/refractory myeloma.